Global Hospital Acquired Infections Diagnostics Market Size Study, by Test (Molecular, Conventional), by Infection (UTI, Pneumonia), by Product (Consumables, Instruments), by Type (Blood Tests, Urinalysis), and Regional Forecasts 2022-2032
The global hospital-acquired infections (HAI) diagnostics market was valued at approximately USD 4.23 billion in 2023 and is anticipated to expand at a CAGR of 1.49% over the forecast period 2024-2032. The alarming rise in the prevalence of HAIs, including surgical site infections, bloodstream infections, ventilator-associated pneumonia, and catheter-associated urinary tract infections, has propelled the demand for rapid and accurate diagnostic solutions. Hospitals, diagnostic laboratories, and healthcare facilities worldwide are increasingly adopting advanced molecular testing methods to curb infection outbreaks and improve patient safety.
The demand for early detection and effective containment of HAIs has intensified, given their impact on hospital mortality rates, prolonged hospital stays, and rising treatment costs. According to the World Health Organization (WHO), nearly 1 in 10 hospitalized patients worldwide is likely to contract an HAI, while the Centers for Disease Control and Prevention (CDC) states that 1 in 31 hospitalized patients in the U.S. acquires an HAI daily. The economic burden associated with HAIs, exceeding USD 28 billion annually in the U.S. alone, further underscores the need for advanced diagnostic tools. The growing threat of multidrug-resistant organisms (MDROs), including methicillin-resistant Staphylococcus aureus (MRSA) and Clostridioides difficile (C. difficile), is driving the adoption of molecular diagnostics such as Polymerase Chain Reaction (PCR)-based tests, enabling early detection and effective treatment strategies.
The conventional diagnostic methods segment held a dominant share of the market in 2023, owing to their established reliability and affordability. However, molecular diagnostics, with its ability to offer rapid pathogen detection, is expected to witness the fastest CAGR of 1.71% during the forecast period. Technological advancements such as real-time PCR, multiplex PCR, and next-generation sequencing (NGS) have significantly enhanced diagnostic accuracy and turnaround times, aiding infection control measures in hospitals and intensive care units (ICUs). For instance, in April 2023, Llusern Scientific introduced the Lodestar DX analyzer for rapid urinary tract infection (UTI) diagnostics, emphasizing the growing shift toward advanced molecular detection techniques.
Geographically, Europe dominated the global market in 2023, capturing the largest share due to stringent hospital infection control policies, extensive healthcare expenditure, and the presence of leading diagnostic manufacturers such as bioMйrieux and QIAGEN. The Asia-Pacific region is projected to exhibit the fastest growth rate, driven by increasing awareness, rising healthcare investments, and an expanding geriatric population more susceptible to HAIs. Countries like China and India are implementing government-led infection monitoring programs to strengthen HIV, tuberculosis, and antibiotic resistance control measures, further driving market growth. Meanwhile, North America remains a strong contender, given its high prevalence of HAIs, well-established healthcare infrastructure, and ongoing R&D efforts in automated molecular diagnostic systems.
Major market players included in this report are:
By Test:
North America
The demand for early detection and effective containment of HAIs has intensified, given their impact on hospital mortality rates, prolonged hospital stays, and rising treatment costs. According to the World Health Organization (WHO), nearly 1 in 10 hospitalized patients worldwide is likely to contract an HAI, while the Centers for Disease Control and Prevention (CDC) states that 1 in 31 hospitalized patients in the U.S. acquires an HAI daily. The economic burden associated with HAIs, exceeding USD 28 billion annually in the U.S. alone, further underscores the need for advanced diagnostic tools. The growing threat of multidrug-resistant organisms (MDROs), including methicillin-resistant Staphylococcus aureus (MRSA) and Clostridioides difficile (C. difficile), is driving the adoption of molecular diagnostics such as Polymerase Chain Reaction (PCR)-based tests, enabling early detection and effective treatment strategies.
The conventional diagnostic methods segment held a dominant share of the market in 2023, owing to their established reliability and affordability. However, molecular diagnostics, with its ability to offer rapid pathogen detection, is expected to witness the fastest CAGR of 1.71% during the forecast period. Technological advancements such as real-time PCR, multiplex PCR, and next-generation sequencing (NGS) have significantly enhanced diagnostic accuracy and turnaround times, aiding infection control measures in hospitals and intensive care units (ICUs). For instance, in April 2023, Llusern Scientific introduced the Lodestar DX analyzer for rapid urinary tract infection (UTI) diagnostics, emphasizing the growing shift toward advanced molecular detection techniques.
Geographically, Europe dominated the global market in 2023, capturing the largest share due to stringent hospital infection control policies, extensive healthcare expenditure, and the presence of leading diagnostic manufacturers such as bioMйrieux and QIAGEN. The Asia-Pacific region is projected to exhibit the fastest growth rate, driven by increasing awareness, rising healthcare investments, and an expanding geriatric population more susceptible to HAIs. Countries like China and India are implementing government-led infection monitoring programs to strengthen HIV, tuberculosis, and antibiotic resistance control measures, further driving market growth. Meanwhile, North America remains a strong contender, given its high prevalence of HAIs, well-established healthcare infrastructure, and ongoing R&D efforts in automated molecular diagnostic systems.
Major market players included in this report are:
- Abbott
- bioMйrieux S.A.
- Hoffmann-La Roche Ltd.
- Siemens Healthcare Private Limited
- Becton, Dickinson and Company (BD)
- QIAGEN
- Thermo Fisher Scientific Inc.
- Meridian Bioscience, Inc.
- Hologic, Inc.
- Cepheid (Danaher Corporation)
- Bio-Rad Laboratories, Inc.
- Luminex Corporation
- GenePOC Inc.
- T2 Biosystems, Inc.
- Accelerate Diagnostics, Inc.
By Test:
- Molecular
- Conventional
- Urinary Tract Infection (UTI)
- Pneumonia
- Surgical Site Infections
- Bloodstream Infections
- Others
- Consumables
- Instruments
- Blood Tests
- Urinalysis
North America
- U.S.
- Canada
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Japan
- China
- India
- Australia
- Thailand
- South Korea
- Brazil
- Argentina
- South Africa
- Saudi Arabia
- UAE
- Kuwait
- Historical Year – 2022
- Base Year – 2023
- Forecast Period – 2024 to 2032
- Market estimates & forecasts from 2022 to 2032.
- Detailed regional and segmental analysis.
- Competitive landscape with insights into key players and strategic developments.
- Investment opportunities, technological advancements, and regulatory frameworks shaping the industry.
- Analysis of market demand-supply dynamics and consumer behavior trends.
CHAPTER 1. GLOBAL HOSPITAL ACQUIRED INFECTIONS DIAGNOSTICS MARKET EXECUTIVE SUMMARY
1.1. Global Hospital Acquired Infections Diagnostics Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Test
1.3.2. By Infection
1.3.3. By Product
1.3.4. By Type
1.4. Key Market Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
CHAPTER 2. GLOBAL HOSPITAL ACQUIRED INFECTIONS DIAGNOSTICS MARKET DEFINITION AND RESEARCH ASSUMPTIONS
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory Frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
CHAPTER 3. GLOBAL HOSPITAL ACQUIRED INFECTIONS DIAGNOSTICS MARKET DYNAMICS
3.1. Market Drivers
3.1.1. Increasing prevalence of HAIs and antimicrobial resistance
3.1.2. Advancements in molecular diagnostic technologies
3.1.3. Growing hospital infection control initiatives
3.2. Market Challenges
3.2.1. High costs associated with advanced diagnostic systems
3.2.2. Stringent regulatory approval processes
3.3. Market Opportunities
3.3.1. Emerging AI-powered diagnostic solutions
3.3.2. Expansion of healthcare infrastructure in developing economies
3.3.3. Increasing investments in R&D for rapid testing methods
CHAPTER 4. GLOBAL HOSPITAL ACQUIRED INFECTIONS DIAGNOSTICS MARKET INDUSTRY ANALYSIS
4.1. Porter’s Five Forces Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s Five Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
CHAPTER 5. GLOBAL HOSPITAL ACQUIRED INFECTIONS DIAGNOSTICS MARKET SIZE & FORECASTS BY TEST (2022-2032)
5.1. Segment Dashboard
5.2. Global Market: Test Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
5.2.1. Molecular Diagnostics
5.2.2. Conventional Diagnostics
CHAPTER 6. GLOBAL HOSPITAL ACQUIRED INFECTIONS DIAGNOSTICS MARKET SIZE & FORECASTS BY INFECTION (2022-2032)
6.1. Segment Dashboard
6.2. Global Market: Infection Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
6.2.1. Urinary Tract Infection (UTI)
6.2.2. Pneumonia
6.2.3. Surgical Site Infections
6.2.4. Bloodstream Infections
6.2.5. Others
CHAPTER 7. GLOBAL HOSPITAL ACQUIRED INFECTIONS DIAGNOSTICS MARKET SIZE & FORECASTS BY PRODUCT (2022-2032)
7.1. Segment Dashboard
7.2. Global Market: Product Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
7.2.1. Consumables
7.2.2. Instruments
CHAPTER 8. GLOBAL HOSPITAL ACQUIRED INFECTIONS DIAGNOSTICS MARKET SIZE & FORECASTS BY TYPE (2022-2032)
8.1. Segment Dashboard
8.2. Global Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
8.2.1. Blood Tests
8.2.2. Urinalysis
CHAPTER 9. GLOBAL HOSPITAL ACQUIRED INFECTIONS DIAGNOSTICS MARKET SIZE & FORECASTS BY REGION (2022-2032)
9.1. North America Hospital Acquired Infections Diagnostics Market
9.1.1. U.S.
9.1.1.1. Test breakdown size & forecasts, 2022-2032
9.1.1.2. Infection breakdown size & forecasts, 2022-2032
9.1.1.3. Product breakdown size & forecasts, 2022-2032
9.1.1.4. Type breakdown size & forecasts, 2022-2032
9.1.2. Canada
9.2. Europe Hospital Acquired Infections Diagnostics Market
9.2.1. U.K.
9.2.2. Germany
9.2.3. France
9.2.4. Spain
9.2.5. Italy
9.2.6. Rest of Europe
9.3. Asia-Pacific Hospital Acquired Infections Diagnostics Market
9.3.1. China
9.3.2. India
9.3.3. Japan
9.3.4. Australia
9.3.5. South Korea
9.3.6. Rest of Asia Pacific
9.4. Latin America Hospital Acquired Infections Diagnostics Market
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa Hospital Acquired Infections Diagnostics Market
9.5.1. Saudi Arabia
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
CHAPTER 10. COMPETITIVE INTELLIGENCE
10.1. Key Company SWOT Analysis
10.1.1. Abbott
10.1.2. bioMйrieux S.A.
10.1.3. Hoffmann-La Roche Ltd.
10.2. Top Market Strategies
10.3. Company Profiles
10.3.1. Abbott
10.3.1.1. Key Information
10.3.1.2. Overview
10.3.1.3. Financial (Subject to Data Availability)
10.3.1.4. Product Summary
10.3.1.5. Market Strategies
10.3.2. bioMйrieux S.A.
10.3.3. Hoffmann-La Roche Ltd.
10.3.4. Siemens Healthcare Private Limited
10.3.5. Becton, Dickinson and Company (BD)
10.3.6. QIAGEN
10.3.7. Thermo Fisher Scientific Inc.
10.3.8. Meridian Bioscience, Inc.
10.3.9. Hologic, Inc.
10.3.10. Cepheid (Danaher Corporation)
CHAPTER 11. RESEARCH PROCESS
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes
1.1. Global Hospital Acquired Infections Diagnostics Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Test
1.3.2. By Infection
1.3.3. By Product
1.3.4. By Type
1.4. Key Market Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
CHAPTER 2. GLOBAL HOSPITAL ACQUIRED INFECTIONS DIAGNOSTICS MARKET DEFINITION AND RESEARCH ASSUMPTIONS
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory Frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
CHAPTER 3. GLOBAL HOSPITAL ACQUIRED INFECTIONS DIAGNOSTICS MARKET DYNAMICS
3.1. Market Drivers
3.1.1. Increasing prevalence of HAIs and antimicrobial resistance
3.1.2. Advancements in molecular diagnostic technologies
3.1.3. Growing hospital infection control initiatives
3.2. Market Challenges
3.2.1. High costs associated with advanced diagnostic systems
3.2.2. Stringent regulatory approval processes
3.3. Market Opportunities
3.3.1. Emerging AI-powered diagnostic solutions
3.3.2. Expansion of healthcare infrastructure in developing economies
3.3.3. Increasing investments in R&D for rapid testing methods
CHAPTER 4. GLOBAL HOSPITAL ACQUIRED INFECTIONS DIAGNOSTICS MARKET INDUSTRY ANALYSIS
4.1. Porter’s Five Forces Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s Five Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
CHAPTER 5. GLOBAL HOSPITAL ACQUIRED INFECTIONS DIAGNOSTICS MARKET SIZE & FORECASTS BY TEST (2022-2032)
5.1. Segment Dashboard
5.2. Global Market: Test Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
5.2.1. Molecular Diagnostics
5.2.2. Conventional Diagnostics
CHAPTER 6. GLOBAL HOSPITAL ACQUIRED INFECTIONS DIAGNOSTICS MARKET SIZE & FORECASTS BY INFECTION (2022-2032)
6.1. Segment Dashboard
6.2. Global Market: Infection Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
6.2.1. Urinary Tract Infection (UTI)
6.2.2. Pneumonia
6.2.3. Surgical Site Infections
6.2.4. Bloodstream Infections
6.2.5. Others
CHAPTER 7. GLOBAL HOSPITAL ACQUIRED INFECTIONS DIAGNOSTICS MARKET SIZE & FORECASTS BY PRODUCT (2022-2032)
7.1. Segment Dashboard
7.2. Global Market: Product Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
7.2.1. Consumables
7.2.2. Instruments
CHAPTER 8. GLOBAL HOSPITAL ACQUIRED INFECTIONS DIAGNOSTICS MARKET SIZE & FORECASTS BY TYPE (2022-2032)
8.1. Segment Dashboard
8.2. Global Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
8.2.1. Blood Tests
8.2.2. Urinalysis
CHAPTER 9. GLOBAL HOSPITAL ACQUIRED INFECTIONS DIAGNOSTICS MARKET SIZE & FORECASTS BY REGION (2022-2032)
9.1. North America Hospital Acquired Infections Diagnostics Market
9.1.1. U.S.
9.1.1.1. Test breakdown size & forecasts, 2022-2032
9.1.1.2. Infection breakdown size & forecasts, 2022-2032
9.1.1.3. Product breakdown size & forecasts, 2022-2032
9.1.1.4. Type breakdown size & forecasts, 2022-2032
9.1.2. Canada
9.2. Europe Hospital Acquired Infections Diagnostics Market
9.2.1. U.K.
9.2.2. Germany
9.2.3. France
9.2.4. Spain
9.2.5. Italy
9.2.6. Rest of Europe
9.3. Asia-Pacific Hospital Acquired Infections Diagnostics Market
9.3.1. China
9.3.2. India
9.3.3. Japan
9.3.4. Australia
9.3.5. South Korea
9.3.6. Rest of Asia Pacific
9.4. Latin America Hospital Acquired Infections Diagnostics Market
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa Hospital Acquired Infections Diagnostics Market
9.5.1. Saudi Arabia
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
CHAPTER 10. COMPETITIVE INTELLIGENCE
10.1. Key Company SWOT Analysis
10.1.1. Abbott
10.1.2. bioMйrieux S.A.
10.1.3. Hoffmann-La Roche Ltd.
10.2. Top Market Strategies
10.3. Company Profiles
10.3.1. Abbott
10.3.1.1. Key Information
10.3.1.2. Overview
10.3.1.3. Financial (Subject to Data Availability)
10.3.1.4. Product Summary
10.3.1.5. Market Strategies
10.3.2. bioMйrieux S.A.
10.3.3. Hoffmann-La Roche Ltd.
10.3.4. Siemens Healthcare Private Limited
10.3.5. Becton, Dickinson and Company (BD)
10.3.6. QIAGEN
10.3.7. Thermo Fisher Scientific Inc.
10.3.8. Meridian Bioscience, Inc.
10.3.9. Hologic, Inc.
10.3.10. Cepheid (Danaher Corporation)
CHAPTER 11. RESEARCH PROCESS
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes
LIST OF TABLES
TABLE 1. Global Hospital Acquired Infections Diagnostics Market, Report Scope
TABLE 2. Global Hospital Acquired Infections Diagnostics Market Estimates & Forecasts by Region, 2022-2032 (USD Million/Billion)
TABLE 3. Global Hospital Acquired Infections Diagnostics Market Estimates & Forecasts by Test, 2022-2032 (USD Million/Billion)
TABLE 4. Global Hospital Acquired Infections Diagnostics Market Estimates & Forecasts by Infection, 2022-2032 (USD Million/Billion)
TABLE 5. Global Hospital Acquired Infections Diagnostics Market Estimates & Forecasts by Product, 2022-2032 (USD Million/Billion)
TABLE 6. Global Hospital Acquired Infections Diagnostics Market Estimates & Forecasts by Type, 2022-2032 (USD Million/Billion)
TABLE 7. North America Hospital Acquired Infections Diagnostics Market Estimates & Forecasts, 2022-2032 (USD Million/Billion)
TABLE 8. Europe Hospital Acquired Infections Diagnostics Market Estimates & Forecasts, 2022-2032 (USD Million/Billion)
TABLE 9. Asia-Pacific Hospital Acquired Infections Diagnostics Market Estimates & Forecasts, 2022-2032 (USD Million/Billion)
TABLE 10. Latin America Hospital Acquired Infections Diagnostics Market Estimates & Forecasts, 2022-2032 (USD Million/Billion)
TABLE 11. Middle East & Africa Hospital Acquired Infections Diagnostics Market Estimates & Forecasts, 2022-2032 (USD Million/Billion)
TABLE 12. Key Market Players and Their Market Share in Hospital Acquired Infections Diagnostics Market
TABLE 13. Competitive Landscape – Key Mergers & Acquisitions in the Market
TABLE 14. Key Investment Opportunities in Hospital Acquired Infections Diagnostics Market
TABLE 15. PESTEL Analysis of the Hospital Acquired Infections Diagnostics Market
TABLE 16. Porter’s Five Forces Analysis of the Market
TABLE 17. Impact of COVID-19 on Hospital Acquired Infections Diagnostics Market
TABLE 18. Technological Advancements in Diagnostic Tools and Techniques
TABLE 19. Regulatory Framework and Guidelines for Hospital Acquired Infections Diagnostics
TABLE 20. Emerging Trends in the Market and Their Impact on Growth
(This list is not complete; the final report contains more than 100 tables. The list may be updated in the final deliverable.)
TABLE 1. Global Hospital Acquired Infections Diagnostics Market, Report Scope
TABLE 2. Global Hospital Acquired Infections Diagnostics Market Estimates & Forecasts by Region, 2022-2032 (USD Million/Billion)
TABLE 3. Global Hospital Acquired Infections Diagnostics Market Estimates & Forecasts by Test, 2022-2032 (USD Million/Billion)
TABLE 4. Global Hospital Acquired Infections Diagnostics Market Estimates & Forecasts by Infection, 2022-2032 (USD Million/Billion)
TABLE 5. Global Hospital Acquired Infections Diagnostics Market Estimates & Forecasts by Product, 2022-2032 (USD Million/Billion)
TABLE 6. Global Hospital Acquired Infections Diagnostics Market Estimates & Forecasts by Type, 2022-2032 (USD Million/Billion)
TABLE 7. North America Hospital Acquired Infections Diagnostics Market Estimates & Forecasts, 2022-2032 (USD Million/Billion)
TABLE 8. Europe Hospital Acquired Infections Diagnostics Market Estimates & Forecasts, 2022-2032 (USD Million/Billion)
TABLE 9. Asia-Pacific Hospital Acquired Infections Diagnostics Market Estimates & Forecasts, 2022-2032 (USD Million/Billion)
TABLE 10. Latin America Hospital Acquired Infections Diagnostics Market Estimates & Forecasts, 2022-2032 (USD Million/Billion)
TABLE 11. Middle East & Africa Hospital Acquired Infections Diagnostics Market Estimates & Forecasts, 2022-2032 (USD Million/Billion)
TABLE 12. Key Market Players and Their Market Share in Hospital Acquired Infections Diagnostics Market
TABLE 13. Competitive Landscape – Key Mergers & Acquisitions in the Market
TABLE 14. Key Investment Opportunities in Hospital Acquired Infections Diagnostics Market
TABLE 15. PESTEL Analysis of the Hospital Acquired Infections Diagnostics Market
TABLE 16. Porter’s Five Forces Analysis of the Market
TABLE 17. Impact of COVID-19 on Hospital Acquired Infections Diagnostics Market
TABLE 18. Technological Advancements in Diagnostic Tools and Techniques
TABLE 19. Regulatory Framework and Guidelines for Hospital Acquired Infections Diagnostics
TABLE 20. Emerging Trends in the Market and Their Impact on Growth
(This list is not complete; the final report contains more than 100 tables. The list may be updated in the final deliverable.)
LIST OF FIGURES
FIG 1. Global Hospital Acquired Infections Diagnostics Market, Research Methodology
FIG 2. Global Hospital Acquired Infections Diagnostics Market, Market Estimation Techniques
FIG 3. Global Market Size Estimates & Forecast Methods
FIG 4. Global Hospital Acquired Infections Diagnostics Market, Key Trends 2023
FIG 5. Global Hospital Acquired Infections Diagnostics Market, Growth Prospects 2022-2032
FIG 6. Global Hospital Acquired Infections Diagnostics Market, Porter’s Five Forces Model
FIG 7. Global Hospital Acquired Infections Diagnostics Market, PESTEL Analysis
FIG 8. Global Hospital Acquired Infections Diagnostics Market, Value Chain Analysis
FIG 9. Global Hospital Acquired Infections Diagnostics Market by Test, 2022 & 2032 (USD Million/Billion)
FIG 10. Global Hospital Acquired Infections Diagnostics Market by Infection, 2022 & 2032 (USD Million/Billion)
FIG 11. Global Hospital Acquired Infections Diagnostics Market by Product, 2022 & 2032 (USD Million/Billion)
FIG 12. Global Hospital Acquired Infections Diagnostics Market by Type, 2022 & 2032 (USD Million/Billion)
FIG 13. Global Hospital Acquired Infections Diagnostics Market, Regional Snapshot 2022 & 2032
FIG 14. North America Hospital Acquired Infections Diagnostics Market, 2022 & 2032 (USD Million/Billion)
FIG 15. Europe Hospital Acquired Infections Diagnostics Market, 2022 & 2032 (USD Million/Billion)
FIG 16. Asia-Pacific Hospital Acquired Infections Diagnostics Market, 2022 & 2032 (USD Million/Billion)
FIG 17. Latin America Hospital Acquired Infections Diagnostics Market, 2022 & 2032 (USD Million/Billion)
FIG 18. Middle East & Africa Hospital Acquired Infections Diagnostics Market, 2022 & 2032 (USD Million/Billion)
FIG 19. Global Hospital Acquired Infections Diagnostics Market, Company Market Share Analysis (2023)
FIG 20. Technological Advancements in Hospital Acquired Infections Diagnostics Tools
(This list is not complete; the final report contains more than 50 figures. The list may be updated in the final deliverable.)
FIG 1. Global Hospital Acquired Infections Diagnostics Market, Research Methodology
FIG 2. Global Hospital Acquired Infections Diagnostics Market, Market Estimation Techniques
FIG 3. Global Market Size Estimates & Forecast Methods
FIG 4. Global Hospital Acquired Infections Diagnostics Market, Key Trends 2023
FIG 5. Global Hospital Acquired Infections Diagnostics Market, Growth Prospects 2022-2032
FIG 6. Global Hospital Acquired Infections Diagnostics Market, Porter’s Five Forces Model
FIG 7. Global Hospital Acquired Infections Diagnostics Market, PESTEL Analysis
FIG 8. Global Hospital Acquired Infections Diagnostics Market, Value Chain Analysis
FIG 9. Global Hospital Acquired Infections Diagnostics Market by Test, 2022 & 2032 (USD Million/Billion)
FIG 10. Global Hospital Acquired Infections Diagnostics Market by Infection, 2022 & 2032 (USD Million/Billion)
FIG 11. Global Hospital Acquired Infections Diagnostics Market by Product, 2022 & 2032 (USD Million/Billion)
FIG 12. Global Hospital Acquired Infections Diagnostics Market by Type, 2022 & 2032 (USD Million/Billion)
FIG 13. Global Hospital Acquired Infections Diagnostics Market, Regional Snapshot 2022 & 2032
FIG 14. North America Hospital Acquired Infections Diagnostics Market, 2022 & 2032 (USD Million/Billion)
FIG 15. Europe Hospital Acquired Infections Diagnostics Market, 2022 & 2032 (USD Million/Billion)
FIG 16. Asia-Pacific Hospital Acquired Infections Diagnostics Market, 2022 & 2032 (USD Million/Billion)
FIG 17. Latin America Hospital Acquired Infections Diagnostics Market, 2022 & 2032 (USD Million/Billion)
FIG 18. Middle East & Africa Hospital Acquired Infections Diagnostics Market, 2022 & 2032 (USD Million/Billion)
FIG 19. Global Hospital Acquired Infections Diagnostics Market, Company Market Share Analysis (2023)
FIG 20. Technological Advancements in Hospital Acquired Infections Diagnostics Tools
(This list is not complete; the final report contains more than 50 figures. The list may be updated in the final deliverable.)
